As per a recent survey by FMI, the global Nasal Antihistamines Market is projected to total US$ 1.9 billion in 2021. Rising preference for alternative modes of drug administration other than injectable and oral is propelling the demand for the nasal drug delivery solutions. Driven by this, the market is expected to reach US$ 3.08 billion by the end of 2031.
Request a report sample to gain comprehensive insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-13708
A significant rise in prevalence of allergies has been witnessed across the world due to the increasing sensitization to allergens and intensifying air pollution. According to the Asthma and Allergy Foundation of America, allergies are the sixth leading cause of chronic illness in the U.S. The country reports over 50 million cases of allergies every year. Increasing demand for speedy relief from allergic reactions such as nose congestion, itchy and runny nose, and sneezing is creating immense sales opportunities for the market.
Several players in the market are focusing on launching novel products to capitalize on this opportunity. For instance, Glenmark Pharma announced launching a new nasal spray named Ryaltris in India in May 2021. In response to a slew of novel product launches, sales are expected to rise at a CAGR of 4.6% during the forecast period 2021-2031.
As per FMI, nasal sprays are the most preferred product available in the nasal antihistamines market, accounting for around 90% of global sales. Attributes such as fast relief, easy to carry, and cost-effectiveness are accelerating the demand for nasal sprays.
“Growing inclination towards the non-invasive treatments and increasing approvals by the Food and Drug Administration (FDA) for over-the-counter (OTC) sales of prescription-based nasal antihistamines are expected to favor the market growth in the coming years,” says the FMI analyst.
Key Takeaways from Nasal Antihistamines Market Study
- The U.S. is expected to hold the largest revenue share in the North America market, accounting for 90.7% of sales in the region in 2021.
- The U.K. is projected to emerge as a highly remunerative market, contributing more than 17.9% of sales in Europe in 2021.
- The market in China is forecast to witness the fastest growth in East Asia, expanding at a CAGR of 6.5% over the assessment period.
- Sales of nasal antihistamines in South Korea and Japan are anticipated to rise at 3.8% and 5.3% CAGR, respectively, by the end of the coming decade.
- Based on distribution channel, retail pharmacies are estimated to account for over 40% of revenue share in the segment, projecting sales growth at a CAGR of 4.4% through 2031.
Discover more about the Nasal Antihistamines analysis@ https://www.futuremarketinsights.com/ask-question/rep-gb-13708
Key Drivers
- Increasing healthcare expenditure, ease in product approvals, and rising funding for life science research, and new product launches are expected to accelerate the growth of the nasal antihistamine market.
- Rising prevalence of respiratory diseases including asthma, allergic rhinitis, and others are fuelling the demand for low-cost generic medical products across China, India, Mexico, Brazil, and South Africa, which is propelling the demand for nasal antihistamines.
Key Restraints
- Side effects associated with nasal antihistamines such as dizziness, dry mouth, and nose, headache, and others is hampering sales of nasal antihistamines.
- Availability of alternatives such as oral antihistamines and others are hindering the growth of nasal antihistamines market.
Competitive Landscape
As per FMI, the global market is dominated by Bayer Healthcare, Novartis AG, Glenmark Pharmaceuticals, GlaxoSmithKline, Cipla, Merck & Co., Sun Pharmaceuticals, Viatris, Proctor & Gamble, Ascend Laboratories, Centaur Pharmaceuticals, J pharmaceuticals, Sato Pharmaceuticals, and Altair Pharmaceuticals.
Leading players are emphasizing on launching new products and receiving regulatory approvals to expand their product portfolios. Some of the manufacturers are aiming at engaging into strategic collaborations, acquisitions, agreement, and merger to increase their market share and expand their global presence. For instance,
- In April 2020, Cipla, an Indian multinational pharmaceutical company, announced receiving final approval for its generic version of Proventil® High Functioning Autism (HFA) Inhalation Aerosol, from the U.S. FDA. The product approval will assist the company to strengthen their presence in the U.S. pharmaceutical market.
- In December 2020, GlaxoSmithKline, a leading pharmaceutical company in India, announced launching a saline wash natural nasal spray, Otrivin Breathe clean. It offers symptomatic relief from allergic rhinitis with moisturizing benefit as it has natural glycerin in it.
We Offer tailor-made Solutions to fit Your Requirements, Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-13708
Some of the key players operating in the market profiled by FMI are:
- Bayer Healthcare LLC
- Novartis AG
- Glenmark Pharmaceuticals
- GlaxoSmithKline
- Sun Pharmaceuticals
- Cipla
- Merck & Co.
- Viatris (Meda Pharmaceuticals)
- Proctor & Gamble
- Ascend Laboratories LLC (Alkem Laboratories)
- Centaur Pharmaceuticals
- J Pharmaceuticals
- Alitair Pharmaceuticals
- Sato Pharmaceuticals
More Valuable Insights on Nasal Antihistamines Market
FMI, in its new report, offers an unbiased analysis of the global nasal antihistamines market, analyzing forecast statistics through 2021 and beyond. The survey reveals growth projections on in nasal antihistamines market with detailed segmentation:
By Product:
- Nasal Spray
- Nasal Drops
By Age Group:
- Adult
- Pediatric
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Stores
Explore Other Reports Links from Healthcare Market
Cosmetic Implants Market:- Global Cosmetic Implants Market is estimated to garner US$ 17.9 Billion while exhibiting a 5.8% CAGR during the forecast period.
Electrosurgery Devices Market:- Electrosurgery Devices Market is valued at US$ 3.3 Billion in 2022 and is expected to reach US$ 5.1 billion by 2032.
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs